SUFFERN, N.Y. , Aug. 25, 2022 /PRNewswire/ -- CDx Diagnostics, Inc. announced that the WATS3D diagnostic platform has been incorporated in the American Gastroenterological Association (AGA) Clinical Practice Update (CPU) on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review, published in Clinical Gastroenterology and Hepatology. WATS3D uses a unique wide-area sampling instrument, proprietary 3D imaging with AI analysis, and expert pathologists to reliably identify abnormal cells to help physicians prevent esophageal cancer.
"The CPU is based on a thorough review of the existing clinical literature and expert opinion. It includes several Best Practice Advice statements intended to provide gastroenterologists with real-world, actionable, practical advice on the management of BE," said Vivek Kaul , MD, FACG, FASGE, AGAF, Segal-Watson Professor of Medicine, Division of Gastroenterology, University of Rochester Medical Center. "The inclusion of WATS3D in this update is an important addition and presents an opportunity for clinicians to potentially increase their detection of BE and esophageal dysplasia, both endoscopically treatable precursors to one of the fastest growing and most fatal cancers in the United States ."
WATS3D technology helps overcome the limitations associated with traditional upper endoscopy screening and surveillance methods. The CPU highlights some WATS3D clinical evidence, which demonstrated an increased yield for dysplasia detection, and that pathologic interpretation of these specimens has been shown to have significantly higher interobserver agreement, with a kappa of 0.86.
"CDx is committed to providing physicians with an AI-based diagnostic solution that empowers them to prevent esophageal cancer," said Bill Huffnagle , CEO of CDx Diagnostics. "The clinical value of adding WATS3D to the upper endoscopy screening and surveillance protocol has now been recognized by 4 major medical societies (AGA, ASGE, AFS, and SAGES). This is a significant accomplishment for CDx which underscores the clinical value of WATS3D and its continued role in preempting this potentially life-threatening disease, one patient at a time."
CDx Diagnostics' mission of Empowering Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time is accomplished through a proprietary diagnostic platform. This combination of technology synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous changes earlier and more reliably than prior methods. CDx tests require only a few minutes of practice time, are highly cost effective, widely reimbursed, and address a recognized critical gap in the current diagnostic standard of care. Routine clinical use of CDx testing has detected thousands of cancers and precancerous conditions that otherwise would have been missed in time for effective treatment. CDx Diagnostics is a Galen Partners portfolio company. To learn more, visit www.cdxdiagnostics.com.
Media contact: Logan Garrett 423.519.9979 lgarrett@bouvierkelly.com
View original content:https://www.prnewswire.com/news-releases/wats3d-ai-platform-included-in-american-gastroenterological-association-aga-clinical-practice-update-on-new-technology-and-innovation-for-surveillance-and-screening-in-barretts-esophagus-301612526.html
Stéphane Bancel discusses the company’s latest Covid shot and prospects for using mRNA in seasonal flu vaccines and personalized treatments for cancer
Investors have lost patience with the slow-paced clinical trials of genetic therapies, and some are using the upbeat news to exit Intellia and peers.
Omeros Corp (NASDAQ: OMER) reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. The company said that in approximately half of the patients died in the narsoplimab group, and narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Omeros adds that despite narso
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
In a recent interview with PEOPLE, the couple, whose real-life love story was portrayed in The Big Sick, opened up about what it's like to be in the immunocompromised community
Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.
A San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.
Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.
One standout in a gloomy stock market this week was Ventyx Biosciences (NASDAQ: VTYX). According to data compiled by S&P Global Market Intelligence, the clinical-stage biotech's shares soared more than 58% higher during the period, thanks to the approval of a drug that hasn't actually been developed by the company. The treatment in question is Bristol Myers Squibb's deucravacitinib (brand name: Sotyktu), which was approved by the U.S. Food and Drug Administration (FDA) last Friday.
J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.
Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for severe COVID-19. WHO continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lowe
The following two healthcare stocks look like great buys for investors seeking to collect both above-average income and increase wealth. The good news for cancer patients is that Merck's (NYSE: MRK) cancer drug called Keytruda is approved in the U.S. to treat 19 different forms of the disease. Looking out over the long term, Merck's pipeline is just as strong as its existing products.
How do you fix a forgetful memory? Neurologist shares brain exercises to keep memory sharp, including reading fiction, cooking from recipes and playing games.
Sen. Lindsey Graham has proposed legislation that would institute a national ban on abortion after 15 weeks, meeting resistsance from both sides of the aisle. Rep. Pramila Jayapal joins Katie Phang to discuss.
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?
Lawmakers hear from scientists about advancements to slow down the aging process
A surgery to remove the problem tissue went "extremely well," her doctor said.
"If we are forcing millions of people into this world, we as a society — whether you are right, whether you are left, whether you are 'pro-life' or not — it doesn't matter. You will all suffer the consequences of a crowded, broken political, healthcare, and education system."View Entire Post ›
Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant's latest offshoots have likely rendered them obsolete. On Thursday, WHO experts said they strongly advised against the use of the two therapies in patients with COVID-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published https://www.bmj.com/content/370/bmj.m3379 in the British Medical Journal. GSK and partner Vir Biotechnology's sotrovimab - which has generated billions in sales and became one of the British drugmaker's top sellers last year - was pulled off the U.S. market by the U.S. Food and Drug Administration (FDA) in April.